Radiation exposure, protection and risk from nuclear medicine procedures

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 6, 2010, Pages 1225-1231

  Salvatori, Massimo ^a   Lucignani, Giovanni ^b,c  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SAN PAOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMIFOSTINE; FLAVONOID; IODINE 131; SOMATOSTATIN;

BONE SCINTISCANNING; CARDIOVASCULAR PROCEDURES; CELL PROTECTION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSIMETRY; HEALTH CARE PERSONNEL; HERBAL MEDICINE; HUMAN; NUCLEAR MEDICINE; RADIATION DOSE; RADIATION EXPOSURE; RADIATION HAZARD; RADIATION PROTECTION; RENAL PROTECTION; REVIEW; XEROSTOMIA;

CAREGIVERS; ENVIRONMENTAL EXPOSURE; FAMILY; HUMANS; MEDICAL STAFF; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY; RADIATION PROTECTION; RADIATION-PROTECTIVE AGENTS; RADIOMETRY; RISK; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77954887745     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1474-5     Document Type: Review

References (20)

1. Mettler Jr FA, Bhargavan M, Faulkner K, Gilley DB, Gray JE, Ibbott GS, et al. Radiologic and nuclear medicine studies in the United States and worldwide: frequency, radiation dose, and comparison with other radiation sources-1950-2007. Radiology. 2009;253(2):520-31.
2. Lucignani G. Radiation burden in myocardial imaging: an old concern in the new age of hi-tech, hybrid imaging. Eur J Nucl Med Mol Imaging. 2010;37(1):169-74.
3. Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD Pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature. J Nucl Med. 2009;50(3):477-84.
4. Sgouros G, Howell RW, Bolch WE, Fisher DR. MIRD commentary: proposed name for a dosimetry unit applicable to deterministic biological effects-the barendsen (Bd). J Nucl Med. 2009;50:485-7.
5. Huang B, Law MW, Khong PL. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology. 2009;251(1):166-74.
6. Fahey FH. Dosimetry of pediatric PET/CT. J Nucl Med. 2009;50:1483-91.
7. Gelfand MJ. Dosimetry of FDG PET/CT and other molecular imaging applications in pediatric patients. Pediatr Radiol. 2009;39 Suppl 1: S46-56.
8. Hosseinimehr SJ. Potential utility of radioprotective agents in the practice of nuclear medicine. Cancer Biother Radiopharm. 2009;24(6):723-31.
9. Ma C, Xie J, Jiang Z, Wang G, Zuo S. Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010. doi: 10.1007/s00259-009-1368-6.
10. Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging. 2009 Nov. 14. [Epub ahead of print].
11. de Carvalho JW, Sapienza M, Ono C, Watanabe T, Guimarães MI, Gutterres R, et al. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I) NaI, on an outpatient basis, be safe? Nucl Med Commun. 2009;30(7):533-41.
12. de Carvalho AB, Jr HJ, Silva AX, Garcia FJ. Use of a voxel phantom as a source and a second voxel phantom as a target to calculate effective doses in individuals exposed to patients treated with 131I. J Nucl Med Technol. 2009;37(1):53-6.
13. Asli IN, Baharfard N, Shafiei B, Tabei F, Javadi H, Seyedabadi M, et al. Relation between clinical and laboratory parameters with radiation dose rates from patients receiving iodine-131 therapy for thyroid carcinoma. Radiat Prot Dosimetry. 2009 Nov. 17 [Epub ahead of print].
14. Stapel AG, van der Zant FM, Gommans GM, Boer RO, Reigman HI. The effects of a custom-made lead collar on dose rates of patients treated with 131I. Health Phys. 2009;96(5 Suppl 2): S64-8.
15. Watanabe H, Satou T, Senzui N, Kimura F, Sano M, Hoshi T, et al. National survey of radiation protection for workers in positron emission tomography facilities in Japan-1st report: occupational role assignment, radiation exposure to medical workers. Nippon Hoshasen Gijutsu Gakkai Zasshi. 2009;65(3):285-94.
16. Kristoffersen US, Gutte H, Skovgaard D, Andersen PA, Kjaer A. Radiation exposure for medical staff performing quantitative coronary perfusion PET with 13N-ammonia. Radiat Prot Dosim. 2010;138(2):107-10.
17. Calandrino R, del Vecchio A, Savi A, Todde S, Belloli S. Intake risk and dose evaluation methods for workers in radiochemistry labs of a medical cyclotron facility. Health Phys. 2009;97(4):315-21.
18. Grassi E, Sghedonia R, Asti M, Fioroni F, Salvo D, Borasi G. Radiation protection in 90Y-labelled DOTA-D-Phe1-Tyr3-octreotide preparations. Nucl Med Commun. 2009;30(12):176-82.
19. Jødal L. Beta emitters and radiation protection. Acta Oncol. 2009;48(2):308-13.
20. Freudenberg LS, Müller SP, Bockis A. Subjective perceptions of patients undergoing radioiodine therapy: why should we know about them? Eur J Nucl Med Mol Imaging. 2009;36(11):1743-4.